Leaders in Pharmaceutical Business Intelligence (LPBI) Group

SIXTH ANNUAL

Companion Diagnostics

Strategy, Partnerships, Technology and Adoption

August 18-19, 2015 | Capital Hilton | Washington, DC | Part of CHI’s Seventh Annual Next Generation Dx Summit

Keynote Session: COMPANION DIAGNOSTICS IN THE CLINIC

NGS offers a powerful tool for assessment of molecular defects found in cancer. The utilization of NGS is becoming common practice in clinical laboratories. This complex technology requires a new level of analytical performance testing and validation. This discussion will focus on approaches used for analytical validation and clinical experience in the MSK-IMPACT program.

Analyses of cancer genomes have revealed mechanisms underlying tumorigenesis and new avenues for therapeutic intervention. In this presentation, I will discuss lessons learned through the characterization of cancer genome landscapes, challenges in translating these analyses to the clinic, and new technologies that have emerged to analyze molecular alterations in the circulation of cancer patients as cell-free tumor DNA. These approaches have important implications for non-invasive detection and monitoring of human cancer, therapeutic stratification, and identification of mechanisms of resistance to targeted therapies.

View Full Agenda & Speaker Abstracts | Register | NextGenerationDx.com/Companion-Diagnostics

Only 2 Weeks Away – Secure your Registration Today and Meet 850+ of your Colleagues!

 Register

For exhibit & sponsorship opportunities, please contact:

Joseph Vacca

Associate Director, Business Development

Cambridge Healthtech Institute

T: (+1) 781-972-5431

E: jvacca@healthtech.com

SOURCE

From: Companion Diagnostics <jimp@nextgenerationdx.com>

Date: Wednesday, August 5, 2015 at 2:17 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Mark Ladanyi and Victor Velculescu / CDx in the Clinic